{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-026132","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.574728+00:00","generated_at":"2026-05-18T05:55:08.740611+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM","bullets":["FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.","RMAT provides expedited FDA review, early interactions, and potential accelerated approval.","Phase 1 data: two patients with low baseline PKP2 showed 110% and 398% increases in protein expression.","Improvements in right ventricular function, ventricular arrhythmias, and KCCQ-12 scores (34-41 pts).","Fifth RMAT designation for Rocket; favorable safety with no dose-limiting toxicities."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-026132","json":"https://secwatch.observer/filing/0001140361-25-026132.json","markdown":"https://secwatch.observer/filing/0001140361-25-026132.md","text":"https://secwatch.observer/filing/0001140361-25-026132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125026132/0001140361-25-026132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125026132/ef20052120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:55:08.740611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}